PharmaCyte Biotech Inc(PMCB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 5:05 AM ET (Korea 9/29 18:05)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.4 | Insider Own | 6.21% | Shs Outstand | 10.7M | Perf Week | -6.85% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 10.1M | Perf Month | -22.27% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | - | Inst Own | 7.11% | Short Float | 0.7% | Perf Quarter | -42.56% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | -3.3% | Short Ratio | 0.35 | Perf Half Y | -40.69% |
| Sales | 0.00B | P/B | 0.16 | EPS next 5Y | - | ROA | -39.47% | Short Interest | 0.07M | Perf YTD | -42% |
| Book/sh | 2.56 | P/C | 0.15 | EPS past 3/5Y | -132.11% -2.4% | ROE | -44.24% | 52W High | -72.19% ($1.51) | Perf Year | -56.71% |
| Cash/sh | 2.84 | P/FCF | - | Sales past 3/5Y | - | ROIC | -54.92% | 52W Low | 25.76% ($0.33) | Perf 3Y | -80.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -422.63% | Gross Margin | - | Volatility(W/M) | 7.16% 11.12% | Perf 5Y | -86.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | -99.1% |
| Dividend Ex-Date | - | Quick Ratio | 40.3 | EPS Q/Q | 56.19% | Profit Margin | - | RSI (14) | 38.68 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 40.3 | Sales Q/Q | - | SMA20 | -7.04% ($0.45) | Beta | 0.66 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -19.3% ($0.52) | Rel Volume | 0.71 | Prev Close | $0.44 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -40.2% ($0.7) | Avg Volume(3M) | 0.20M | Price | $0.42 |
| IPO | 2003/9/11 | Option/Short | Yes/Yes | Trades | 168 | Volume | 142,299 | Change | -4.78% |
🧫 This clinical-stage biotech develops cell therapies that use its proprietary '<strong>Cell-in-a-Box®</strong>' technology—encapsulating living cells in thin capsules—to target diseases such as pancreatic cancer, malignant ascites, and diabetes. Its lead pipeline candidate, CypCaps, is designed to act like an "artificial bio-liver," activating inactive chemotherapy drugs at the tumor site. The company is a nano-cap listed on the Nasdaq.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded less than usual That is 71% of its average volume.
PMCB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #554 of 592 in the industry
Based on market cap of $5M.
GRI#552 GRI Bio Inc $5M PER - 
DRMA#553 Dermata Therapeutics Inc $5M PER - PMCB#554 PharmaCyte Biotech Inc $5M PER - 
SXTP#555 60 Degrees Pharmaceuticals Inc $4M PER - 
DCOY#556 Decoy Therapeutics Inc $4M PER - 
FAQ
What kind of company is PMCB?
PMCB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PMCB?
The market cap of PMCB is approximately $5M, ranking 5,712 within its sector.
What is the 52-week high and low for PMCB?
PMCB has recorded a 52-week high of $1.51 and a low of $0.33.
